Close Menu

NEW YORK – Anticancer Bioscience (ACB) on Monday said it has raised ¥63 million ($10 million) in a financing round led by undisclosed angel investors and plans to use the funds to advance its synthetic lethality programs, including drugs targeting MYC overexpression.

ACB, a Chengdu, China-based company that uses proprietary screening libraries and discovery platforms to develop new ways to induce cancer cell death while sparing healthy tissue, anticipates the funds will allow it to take two compounds into investigational new drug (IND) application-enabling studies this year.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

The emergence of cell clones that are resistant to targeted therapies poses a significant issue in the treatment of metastatic melanoma.

Sponsored by

This webinar, the second in our Next-Generation Proteomics for Precision Oncology series, will discuss how unbiased discovery proteomics can be used to identify new key mechanisms and signatures supporting clinical decision-making for melanoma patients.

Sponsored by
Canexia Health

Last year, by Precision Oncology News' count, the FDA approved 27 precision oncology drugs, a 35 percent increase in the number of approvals from 2019.